Isotretinoin

Overview

Isotretinoin (Accutane®) is a synthetic second-generation retinoid that may be useful in the treatment of a variety of dermatologic conditions associated with abnormal epithelial cell proliferation and differentiation in dogs and cats. Although it has been used for several dermatologic disorders, scientific evidence supporting its use in veterinary medicine remains limited.

Following oral administration, isotretinoin is rapidly absorbed after capsule disintegration, although only about 25% of the administered dose reaches the systemic circulation. Absorption is increased when administered with food or milk. The drug is metabolized in the liver and eliminated in both urine and feces.

Mechanism of Action (MOA): Isotretinoin regulates epithelial cell proliferation and differentiation, although its exact mechanism of action is unknown. It reduces sebaceous gland size and activity, thereby decreasing sebum production. In addition, it possesses anti-keratinization and anti-inflammatory effects, may indirectly reduce bacterial populations within sebaceous pores, and influences monocyte and lymphocyte function, resulting in alterations in cellular immune responses.

Indications

Isotretinoin may be useful for the management of selected dermatologic disorders associated with abnormal keratinization, follicular abnormalities, and sebaceous gland disease in dogs and cats. Clinical evidence supporting its use in veterinary medicine remains limited.

• Follicular and keratinization disorders (dogs): Including follicular dysplasias (e.g., color dilution alopecia), lamellar ichthyosis, idiopathic seborrhea, intracutaneous cornifying epitheliomas, and multiple epidermal inclusion cysts.
• Sebaceous gland disorders (dogs and cats): Used for sebaceous adenitis and other disorders involving abnormal sebaceous gland function.
• Benign proliferative skin lesions (dogs): Including keratoacanthoma, benign pilomatrixomas, and Schnauzer comedo syndrome.
• Cutaneous neoplasia: Used as palliative therapy for epitheliotropic (cutaneous T-cell) lymphoma in dogs.
• Dermatologic disorders in cats: May be used for actinic keratosis, solar-induced squamous cell carcinoma, Bowen’s disease (multicentric in situ squamous cell carcinoma), and feline acne.

Dosage (Reference)

Dog

In dogs, isotretinoin dosage varies depending on the dermatologic condition being treated. Because no well-controlled prospective clinical studies are available, dosage recommendations are based on clinical experience. The drug should be administered with food to improve absorption.

Cat

In cats, isotretinoin has limited reported clinical use. Suggested dosages are available for selected dermatologic conditions and palliative treatment of epitheliotropic lymphoma.

Warnings & Precautions

Isotretinoin is a potent retinoid with significant safety concerns, particularly its teratogenic potential. Careful patient selection and appropriate handling precautions are essential before initiating therapy.

• Pregnancy: Contraindicated during pregnancy because isotretinoin is a known teratogen. It should not be used in pregnant animals or in animals living in households with pregnant women.
• Breeding animals: Do not use in breeding animals or intact females; isotretinoin also appears to inhibit spermatogenesis.
• Lactation: It is not known whether isotretinoin passes into milk, and it is not recommended for use in lactating animals.
• Hypertriglyceridemia: Use with caution in patients with hypertriglyceridemia.
• Renal or hepatic disease: Use cautiously in patients with severe renal or hepatic disease, and only when the potential benefits outweigh the risks.
• Hypersensitivity: Isotretinoin is contraindicated during pregnancy and in patients with known hypersensitivity to isotretinoin, vitamin A, or formulation components. In animals with hypertriglyceridemia or severe hepatic or renal disease, use only when anticipated benefits outweigh risks, with appropriate monitoring.
• Sunlight exposure: Avoid excessive exposure to sunlight because retinoids enhance the effects of ultraviolet (UV) light.
• Hazardous drug: Isotretinoin is classified by NIOSH as a hazardous drug. Pregnant women must avoid contact with the medication, and it should not be dispensed to households with pregnant women; women of childbearing age should not handle it.

Drug Interactions

Clinically significant drug interactions with isotretinoin are primarily related to additive retinoid toxicity, altered drug concentrations, or an increased risk of specific adverse effects. Additional monitoring is recommended when these drugs are used concurrently.

• Vitamin A or other retinoids (e.g., etretinate, tretinoin): Concurrent use may result in additive toxic effects and should be avoided.
• Corticosteroids (e.g., dexamethasone, prednisolone): Concomitant administration may further increase the risk of osteoporosis.
• Cyclosporine: Isotretinoin may increase cyclosporine concentrations.
• Tetracyclines: Concurrent use may increase the risk of pseudotumor cerebri (cerebral edema and increased cerebrospinal fluid pressure), and the combination should be avoided.

Side Effects & Overdose

Side Effects

Adverse effects of isotretinoin are generally uncommon in dogs but may occur more frequently in cats. Most reported effects involve the eyes, gastrointestinal tract, skin, or central nervous system.

• Keratoconjunctivitis sicca (KCS): The most common adverse effect reported in dogs; not reported in cats.
• Gastrointestinal effects: Anorexia, vomiting, diarrhea, and abdominal distention may occur. In cats, anorexia, diarrhea, and associated weight loss have been reported.
• CNS effects: Lassitude, hyperactivity, behavioral changes, and collapse may occur in dogs.
• Dermatologic effects: Pruritus, exfoliative dermatitis, erythema of the feet and mucocutaneous junctions, and cheilitis have been reported.
• Other effects: Stiffness of limbs, polydipsia, and swollen tongue may occur in dogs. Cats may develop blepharospasm, periocular crusting, and erythema.
• Dose adjustment: If adverse effects develop, extending the dosing interval (e.g., alternating daily and every-other-day administration) may reduce the total drug exposure.
• Skeletal effects: With long-term treatment, skeletal abnormalities may develop, including premature closure of the epiphyses in growing animals, cortical hyperostosis, periosteal calcification and long-bone demineralization.

Overdose

Information regarding acute isotretinoin overdose in veterinary patients is limited. Management is primarily supportive and directed at minimizing gastrointestinal absorption when appropriate.

• Hypersalivation: A common finding in dogs following overdose.
• Gastrointestinal decontamination: Consider appropriate GI decontamination protocols following acute overdose when warranted.
• Supportive care: Monitor the patient and provide supportive treatment based on the clinical signs present.

Key Notes

Practical clinical points that help optimize the safe and effective use of isotretinoin in dogs and cats:

• Delayed clinical response: Therapeutic improvement may not become apparent for 6–8 weeks; treatment should not be judged ineffective prematurely.
• Administration with food: Oral administration with food or milk improves systemic absorption and may enhance therapeutic response.
• Species tolerance: Dogs generally tolerate isotretinoin better than cats, in which adverse effects may limit long-term use.
• Availability: Obtaining isotretinoin for veterinary patients may be difficult because access is restricted by some manufacturers and distributors.
• Treatment monitoring: Routine assessment of treatment response and periodic monitoring of liver enzymes, Schirmer tear test (dogs), or body weight (cats) can help identify adverse effects during prolonged therapy.